Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Prostate Cancer Prostatic Dis. 2009;12(3):269-76. doi: 10.1038/pcan.2009.8. Epub 2009 Mar 17.


We assessed self-reported health-related quality of life (HRQoL) and longitudinal changes in sex hormones among 86 prostate cancer (PCa) patients without distant metastases 5 years after radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment. HRQoL outcomes were compared with scores from age-matched controls without a cancer diagnosis (NORM). Compared with NORM, patients scored statistically (P<0.05) and clinically (effect size >or=0.4) lower on sexual domains, and statistically (P<0.05) lower on physical function and vitality. Estimated free testosterone and measured serum estradiol had increased from baseline in most patients, but did not correlate with HRQoL outcomes 5 years after the start of treatment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Combined Modality Therapy
  • Follicle Stimulating Hormone / blood
  • Gonadal Steroid Hormones / blood
  • Humans
  • Luteinizing Hormone / blood
  • Male
  • Middle Aged
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / psychology
  • Prostatic Neoplasms / therapy*
  • Quality of Life*


  • Androgen Antagonists
  • Gonadal Steroid Hormones
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Prostate-Specific Antigen